参考文献/References:
[1].Korita I,Bulo A,Langlois MR , et al.Inflammation patients with cardiovascular disease and metabolic syndrome[J]. J Med Biochem,2013,32: 214-219.
[2].Knoflach M, Kiechl S, Mantovani A, et al. Pentraxin-3 as a marker of advanced atherosclerosis results from the Bruneck, ARMY and ARFY Studies[J]. PLoS One, 2012,7(2):e31474.
[3].Vilahur G , Badimon L.Biological actions of pentraxins, Vasc[J]. Pharmacol,2015,73:38-44.
[4].Presta M , Camozzi M , Salvatori G , et al. Role of the soluble pattern recognition receptor PTX3 in vascular biology[J].J Cell Mol Med,2007,11(4):723-738.
[5].Cappuzzello C, Doni A, Dander E, et al. Mesenchymal stromal cell-derived PTX3 promotes wound healing via fibrin remodeling[J]. J Invest Dermatol,2016,136(1):293-300.
[6].Bonacina F, Barbieri SS, Cutuli L, et al. Vascular pentraxin 3 controls arterial thrombosis by targeting collagen and fibrinogen induced platelets aggregation[J]. Biochim Biophys Acta,2016,1862(6):1182-1190.
[7].Bottazzi B, Inforzato A, Messa M, et al. The pentraxins PTX3 and SAP in innate immunity, regulation of inflammation and tissue remodelling[J].J Hepatology, 2016,64(6):1416-1427.
[8].Quercioli A, Pataky Z, Montecucco F, et al,Coronary vasomotor control in obesity and morbid obesity: contrasting flow responses with endocannabinoids, leptin, and inflammation[J].JACC Cardiovasc Imaging,2012,5(8):805-815.
[9].Hill AL, Lowes DA, Webster NR, et al. Regulation of pentraxin-3 by antioxidants[J].Br J Anaesth,2009,103(6) :833-839.
[10].Carrizzo A, Lenzi P, Procaccini C, et al. Pentraxin 3 induces vascular endothelial dysfunction through a Pselectin/matrix metalloproteinase-1 pathway[J].Circulation,2015,131(17):1495-1505.
[11].O’Neill CL, Guduric-Fuchs J , Chambers SE , et al.Endothelial cell-derived pentraxin 3 limits the vasoreparative therapeutic potential of circulating angiogenic cells[J].Cardiovasc Res,2016,112(3):677-688.
[12].Ishino M, Shishido T, Suzuki S, et al. Deficiency of long pentraxin PTX3 promoted neointimal hyperplasia after vascular injury[J].J Atheroscler Thromb,2015,22(4):372-378.
[13]. Qiu L, Xu R,Wang S, et al. Honokiol ameliorates endothelial dysfunction through suppression of PTX3 expression, a key mediator of IKK/IkappaB/NF-kappaB, in atherosclerotic cell model[J].Exp Mol Med,2015,47:e171.
[14].Tomohiko Y, Satoshi I, Seiji K, et al. Plasma pentraxin 3 is a more potent predictor of endothelial dysfunction than high-sensitive C-reactive protein[J].Int Heart J,2014,55(2):160-164.
[15].Yilmaz MI, Solak Y, Saglam M, et al. The relationship between IL-10 levels and cardiovascular events in patients with CKD[J].Clin J Am Soc Nephrol,2014,9(7):1207-1216.
[16].Kanbay A.Correlation between pentraxin-3 and endothelial dysfunction in obstructive sleep apnea syndrome[J].Ann Thorac Med,2015,10(3):199-203.
[17].Luo Q,Han X. Second-trimester maternal serum markers in the prediction of preeclampsia[J].J Perinat Med,2017,45(7):809-816.
[18].Naito A,Tanabe N, Jujo T, et al.Pentraxin3 in chronic thromboembolic pulmonary hypertension: a new biomarker for screening from remitted pulmonary thromboembolism[J].PLoS One,2014,9(11):e113086.
[19].Simon A,Subra JF, Guilpain P, et al.Detection of anti-pentraxin-3 autoantibodies in ANCAassociated vasculitis[J].PLoS One,2016,11(1):e0147091.
[20].Cieslik P ,Hrycek A .Pentraxin 3 as a biomarker of local inflammatory response to vascular injury in systemic lupus erythematosus[J].Autoimmunity,2015,48 (4):242-250.
[21].Matsuura Y, Hatakeyama K, Imamura T, et al.Different distribution of pentraxin 3 and C-reactive protein in coronary atherosclerotic plaques[J].J Atheroscler Thromb,2012,19 (9):837-845.
[22].Zempo-Miyaki A, Fujie S, Sato K,et al.Elevated pentraxin 3 level at the early stage of exercise training is associated with reduction of arterial stiffness in middle-aged and older adults[J].J Hum Hypertens,2016,30(9):521-526.
[23].Kadir O,Omer K,Tolga D,et al.Pentraxin 3 is a predictor for fibrosis and arterial stiffness in patients with nonalcoholic fatty liver disease[J].Gastroenterol Res Pract,2016,2016:1417962.
[24].Kahlow BS,Petisco R,Skare TL,et al.Serum pentraxin 3 levels are negatively associated with carotid intima media thickness in non-obese rheumatoid arthritis patients[J].Int J Cardiol,2016,221:298-301.
[25].Tazaki R, Tanigawa J, Fujisaka T, et al. Plasma pentraxin3 level is associated with plaque vulnerability assessed by optical coherence tomography in patients with coronary artery disease[J].Int Heart J,2016,57(1):18-24.
[26].Peri G, Introna M,Corradi D, et al. A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans[J].Circulation,2000,102 (6):636-641.
[27].Lee R,Ahn HR,Shin MH,et al.Association of plasma pentraxin-3 level with lipid levels and cardiovascular risk factors in people with no history of lipid-lowering medication: the dong-gu study[J].J Atheroscler Thromb,2019,Jan 23. doi: 10.5551/jat.47167.
[28].Ozkaramanli Gur D , Gur O, Guzel S,et al. Inflammatory mediators across the spectrum of ankle-brachial index[J]. J Atheroscler Thromb, 2019,26(4):351-361.
[29].Salio M, Chimenti S, de Angelis N, et al. Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction[J]. Circulation,2008,117(8):1055-1064.
[30].Zhu H, Cui D, Liu K, et al.Long pentraxin PTX3 attenuates ischemia reperfusion injury in a cardiac transplantation model[J]. Transpl Int,2014,27(1):87-95.
[31].Morishita T, Uzui H, Nakano A, et al. Association of plasma pentraxin-3 levels with coronary risk factors and the lipid profile: a cross-sectional study in Japanese patients with stable angina pectoris[J]. Heart & Vessels, 2018,33(11):1301-1310.
[32].Guo R , Li Y , Wen J , et al, Elevated plasma level of pentraxin-3 predicts in-hospital and 30-day clinical outcomes in patients with non-ST-segment elevation myocardial infarction who have undergone percutaneous coronary intervention[J].Cardiology,2014,129(3) :178-188.
[33].Altay S, ?akmak HA, Kemalo?lu ?z T, et al.Long-term prognostic significance of pentraxin-3 in patients with acute myocardial infarction: 5-year prospective cohort study[J].Anatol J Cardiol,2017,17(3):202-209.
[34].Jenny NS,Arnold AM, Kuller LH, et al. Associations of pentraxin 3 with cardiovascular disease and all-cause death: the Cardiovascular Health Study[J].Arterioscler Thromb Vasc Biol,2009,29(4):594-599.
[35].Montecucco F, Liberale L, Bonaventura A, et al. The role of inflammation in cardiovascular outcome[J].Curr Atheroscler Rep,2017,19(3) :11.
[36].Haybar H,Parsa SA,Khaheshi I.Pentraxin level is the key to determine primary Percutaneous Coronary Intervention (PCI) or fibrinolysis[J].Cardiovasc Hematol Disord Drug Targets,2018,Nov 20. doi: 10.2174/1871529X19666181120161810.
[37].Horckmans M,Ring L,Duchene J, et al. Neutrophils orchestrate post-myocardial infarction healing by polarizing macrophages towards a reparative phenotype[J].Eur Heart J,2017,38(3):187-197.
[38].Vengen IT,Enger TB,Videm V,et al. Pentraxin 3, ficolin-2 and lectin pathway associated serine protease MASP-3 as early predictors of myocardial infarction - the HUNT2 study[J]. Sci Rep ,2017,7:43045.
[39].Cappuzzello C, Doni A, Dander E, et al.Mesenchymal stromal cellderived PTX3 promotes wound healing via fibrin remodeling[J].J Invest Dermatol,2016,136(1):293-300.
[40].George M, Shanmugam E, Srivatsan V, et al.Value of pentraxin-3 and galectin-3 in acute coronary syndrome: a short-term prospective cohort study[J].Ther Adv Cardiovasc Dis,2015,9(5):275-284.
[41].Liu H,Guo X,Yao K,et al.Pentraxin- 3 predicts long-term cardiac events in patients with chronic heart failure[J].Biomed Res Int,2015,2015:817615.
相似文献/References:
[1]李乐亮,综述,李萍,等.炎症标志物与颈动脉粥样斑块的稳定性[J].心血管病学进展,2016,(3):219.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.001]
LI Leliang,LI Ping.Stability of Inflammatory Markers and Carotid Artery Plaque[J].Advances in Cardiovascular Diseases,2016,(5):219.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.001]
[2]耿春晖 关秀茹.MicroRNA作为动脉粥样硬化的诊断生物标志物的研究进展[J].心血管病学进展,2019,(7):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
GENG Chunhui,GUAN Xiuru.microRNA as a Diagnostic Biomarker for Atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(5):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
[3]乐健 何胜虎.前蛋白转化酶枯草溶菌素9致动脉粥样硬化的机制研究进展[J].心血管病学进展,2019,(7):1000.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.009]
YUE Jian,HE Shenghu.Advances in the mechanism of PCSK9-induced atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(5):1000.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.009]
[4]武亚琳,梁斌,杨志明.NLRP3/IL-1β途径的促动脉粥样硬化作用及临床应用[J].心血管病学进展,2019,(6):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
WU Yalin,LIANG Bin,YANG Zhiming.The Role of NLRP3/IL-1in Atherosclerosis and Clinical Application[J].Advances in Cardiovascular Diseases,2019,(5):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
[5]李琦玉 ?张宁 陈婧 黄浙勇.动脉粥样硬化的抗血小板分子靶向治疗[J].心血管病学进展,2019,(5):701.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.010]
LI Qiyu,ZHANG Ning,CHEN Jing,et al.Anti-Platelet Molecular Targeted Therapy or Atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(5):701.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.010]
[6]焦新峰 刘正霞 鲁翔.白介素-8在冠心病中的研究进展[J].心血管病学进展,2019,(8):1126.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.014]
JIAO Xinfeng,LIU Zhengxia,LU Xiang.Research Progress of Interleukin-8 in Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(5):1126.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.014]
[7]徐侨 刘正霞 鲁翔.白介素22在动脉粥样硬化和2型糖尿病中的作用[J].心血管病学进展,2019,(9):1260.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.019]
XU Qiao,LIU Zhengxia,LU Xiang.IL-22 in Atherosclerosis and Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(5):1260.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.019]
[8]石文坚 花蕾 孟祥光 袁义强.环状RNA在冠状动脉粥样硬化性心脏病中的研究进展[J].心血管病学进展,2019,(9):1286.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.026]
SHI Wenjian,HUA Lei,MENG Xiangguang,et al.CircRNA in Coronary Atherosclerotic Heart Disease[J].Advances in Cardiovascular Diseases,2019,(5):1286.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.026]
[9]代承忠 彭礼清 余建群 刘静 蒲华霞.双源CT血管成像评价经导管主动脉瓣置入术术前患者颈动脉斑块[J].心血管病学进展,2019,(8):1182.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.028]
DAI Chengzhong,PENG Liqing,YU Jianqun,et al.Evaluation of Carotid Arteries Plaques in Patients Referred for TAVI with Dual-source CT Angiography[J].Advances in Cardiovascular Diseases,2019,(5):1182.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.028]
[10]林春尧 刘晓辉.IL-33/ST2在冠心病中的研究进展[J].心血管病学进展,2020,(2):128.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.007]
LIN Chunyao LIU Xiaohui.IL-33/ST2 in Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2020,(5):128.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.007]